Isoprenaline

beta-Adrenergic Agonist — CARDIOVASCULAR SYSTEM

Key facts

Isoprenaline is an ofp drug in the beta-Adrenergic Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1956. Its mechanism of action is classified as Adrenergic beta-Agonists. DrugCentral lists 40 molecular targets, including ADRB2, ADRB1 and ADRB3. Recorded indications include Atrioventricular block, Cardiac arrest, Common cold and Hypovolemic shock.

• Approval status: ofp (first approved 1956 by the FDA).
• Drug class: beta-Adrenergic Agonist.
• Mechanism of action: Adrenergic beta-Agonists.
• Molecular targets: ADRB2, ADRB1, ADRB3 and TAS2R1 (40 listed in DrugCentral).
• Indications: Atrioventricular block, Cardiac arrest, Common cold, Hypovolemic shock and Low cardiac output syndrome and others.
• ATC code: C01CA02 (Adrenergic and dopaminergic agents).
• Molecular formula: C11H17NO3; molecular weight 211.26 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Atrioventricular block
• Cardiac arrest
• Common cold
• Hypovolemic shock
• Low cardiac output syndrome
• Syncope due to Heart Block
• Thick Bronchial Secretions

Contraindications (11)

• Angina pectoris
• Atrioventricular Conduction Defect
• Chronic myocardial ischemia
• Diabetes mellitus
• Digitalis Toxicity with AV Conduction Defects
• Disorder of coronary artery
• Hypertensive disorder
• Hyperthyroidism
• Myocardial infarction
• Tachyarrhythmia
• Tachycardia due to Digitalis Toxicity

Mechanism & targets

• Mechanism of action (MoA): Adrenergic beta-Agonists
• Established pharmacologic class: beta-Adrenergic Agonist

Molecular targets (40)

Target	Gene	Action	Activity
Beta-2 adrenergic receptor	ADRB2	agonist	EC50 9.80
Beta-1 adrenergic receptor	ADRB1	agonist	EC50 9.00
Beta-3 adrenergic receptor	ADRB3	agonist	EC50 8.50
Taste receptor type 2 member 1	TAS2R1	unknown	EC50 8.31
Taste receptor type 2 member 14	TAS2R14	unknown	EC50 8.31
Taste receptor type 2 member 46	TAS2R46	unknown	EC50 8.31
Taste receptor type 2 member 5	TAS2R5	unknown	EC50 8.31
Taste receptor type 2 member 4	TAS2R4	unknown	EC50 8.31
Taste receptor type 2 member 3	TAS2R3	unknown	EC50 8.31
Taste receptor type 2 member 38	TAS2R38	unknown	EC50 8.31
Taste receptor type 2 member 39	TAS2R39	unknown	EC50 8.31
Taste receptor type 2 member 40	TAS2R40	unknown	EC50 8.31
Taste receptor type 2 member 41	TAS2R41	unknown	EC50 8.31
Taste receptor type 2 member 43	TAS2R43	unknown	EC50 8.31
Taste receptor type 2 member 31	TAS2R31	unknown	EC50 8.31
Taste receptor type 2 member 45	TAS2R45	unknown	EC50 8.31
Taste receptor type 2 member 30	TAS2R30	unknown	EC50 8.31
Taste receptor type 2 member 19	TAS2R19	unknown	EC50 8.31
Taste receptor type 2 member 20	TAS2R20	unknown	EC50 8.31
Taste receptor type 2 member 50	TAS2R50	unknown	EC50 8.31

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1956-03-09	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C01CA02	CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES › Adrenergic and dopaminergic agents
R03AB02	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Non-selective beta-adrenoreceptor agonists
R03AK02	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
R03CB01	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS FOR SYSTEMIC USE › Non-selective beta-adrenoreceptor agonists
R03CB51	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS FOR SYSTEMIC USE › Non-selective beta-adrenoreceptor agonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Toxic epidermal necrolysis	193.9
Drug ineffective	182.3
Torsade de pointes	157.7
Ventricular tachycardia	88.7
Ventricular fibrillation	73.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Isoprenaline is on its molecule page.

• Molecular formula: C₁₁H₁₇NO₃
• Molecular weight: 211.26 g/mol
• CAS number: 7683-59-2
• InChIKey: JWZZKOKVBUJMES-UHFFFAOYSA-N
• PubChem CID: 3779

CC(C)NCC(O)C1=CC=C(O)C(O)=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Isoprenaline used for?

DrugCentral lists the following indications for Isoprenaline: Atrioventricular block, Cardiac arrest, Common cold, Hypovolemic shock, Low cardiac output syndrome, Syncope due to Heart Block and Thick Bronchial Secretions.

How does Isoprenaline work?

Isoprenaline is classified as Adrenergic beta-Agonists; its molecular targets in DrugCentral include ADRB2 (agonist), ADRB1 (agonist), ADRB3 (agonist) and TAS2R1.

When was Isoprenaline first approved?

Isoprenaline was first approved by the FDA in 1956.

What drug class does Isoprenaline belong to?

Isoprenaline is in the beta-Adrenergic Agonist class.

What is the chemical formula of Isoprenaline?

Isoprenaline has the molecular formula C11H17NO3 and a molecular weight of 211.26 g/mol.

Sources

• DrugCentral drug card 1499 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1711 — compound record and bioactivity
• PubChem CID 3779 — chemical identifiers
• DrugBank DB01064 — drug record
• FDA UNII L628TT009W — substance identity
• DailyMed: FDA labels for Isoprenaline — current prescribing information (label search)
• UniProt P07550 (ADRB2) — target protein
• UniProt P08588 (ADRB1) — target protein
• UniProt P13945 (ADRB3) — target protein
• UniProt Q9NYW7 (TAS2R1) — target protein
• UniProt Q9NYV8 (TAS2R14) — target protein
• UniProt P59540 (TAS2R46) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.